List view / Grid view

H. Lundbeck A/S

 

news

Otsuka and Lundbeck receive positive CHMP opinion for Abilify Maintena(r) in schizophrenia

21 September 2013 | By

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommending marketing authorisation for Abilify Maintena (aripiprazole), an intramuscular (IM) depot formulation for the maintenance treatment of schizophrenia in adult patients stabilised…

news

Lundbeck presents new data on Selincro

8 April 2013 | By H. Lundbeck A/S

New data on Selincro from three phase III studies that show a significant reduction in alcohol consumption in alcohol dependent patients with high risk drinking level...

news

Patient groups give Lundbeck top marks

14 January 2013 | By H. Lundbeck A/S

Lundbeck took first place in a global survey, in which 600 patient groups around the world evaluated the ability of 29 pharmaceutical companies to meet patient expectations...